Peptide Library
Semaglutide vs Tirzepatide vs Retatrutide
The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| What it is | GLP-1 agonist, weight & glucose control | Dual GIP/GLP-1 agonist: weight & glucose control | Triple incretin agonist: metabolic health and weight loss |
| Type | GLP-1 receptor agonist | GIP/GLP-1 dual agonist | Tri-agonist (GIP/GLP-1/Gcgr) |
| Structure | 31 aa, GLP-1 analog | 39 aa, lipidated peptide (Eli Lilly) | 39 aa, lipidated peptide (Eli Lilly) |
| Status | FDA approved | — | — |
| Route | SC, heti 1× / weekly | — | — |
| Storage | 2–8°C | 2–8°C (reconstituted) | 2–8°C (reconstituted) |
| Source | Placeholder, image later | — | — |
| Molecular weight | — | ~4814 Da | ~4824 Da |
| Target area | — | T2DM, obesity | Weight loss, T2DM |
| Stability | — | ~30 days (reconstituted) | ~28 days (reconstituted) |
| Full entry | Open → | Open → | Open → |
What it is
SemaglutideGLP-1 agonist, weight & glucose control
TirzepatideDual GIP/GLP-1 agonist: weight & glucose control
RetatrutideTriple incretin agonist: metabolic health and weight loss
Type
SemaglutideGLP-1 receptor agonist
TirzepatideGIP/GLP-1 dual agonist
RetatrutideTri-agonist (GIP/GLP-1/Gcgr)
Structure
Semaglutide31 aa, GLP-1 analog
Tirzepatide39 aa, lipidated peptide (Eli Lilly)
Retatrutide39 aa, lipidated peptide (Eli Lilly)
Status
SemaglutideFDA approved
Tirzepatide—
Retatrutide—
Route
SemaglutideSC, heti 1× / weekly
Tirzepatide—
Retatrutide—
Storage
Semaglutide2–8°C
Tirzepatide2–8°C (reconstituted)
Retatrutide2–8°C (reconstituted)
Source
SemaglutidePlaceholder, image later
Tirzepatide—
Retatrutide—
Molecular weight
Semaglutide—
Tirzepatide~4814 Da
Retatrutide~4824 Da
Target area
Semaglutide—
TirzepatideT2DM, obesity
RetatrutideWeight loss, T2DM
Stability
Semaglutide—
Tirzepatide~30 days (reconstituted)
Retatrutide~28 days (reconstituted)